The effect of CYP2J2, CYP3A4, CYP3A5 and the MDR1 C3435T polymorphisms and gender on the urinary excretion of the metabolites of the H1-receptor antihistamine ebastine: A pilot study

British Journal of Clinical Pharmacology

Volumn 62, Issue 2, 2006, Pages 177-186

  Gervasini, Guillermo ^a,b   Vizcaino, Sonia ^a   Carrillo, Juan Antonio ^a   Caballero, Maria Jesus ^a   Benitez, Julio ^a  

^a HOSPITAL INFANTA CRISTINA   (Spain)

^b UNIVERSITY OF EXTREMADURA   (Spain)

Author keywords

Ebastine; Gender; Polymorphism

Indexed keywords

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BEVERAGES; BODY WEIGHT; BUTYROPHENONES; CITRUS PARADISI; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENOTYPE; HISTAMINE H1 ANTAGONISTS; HUMANS; MALE; OXYGENASES; P-GLYCOPROTEIN; PILOT PROJECTS; PIPERIDINES; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; SEX FACTORS;

EID: 33748360334     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02578.x     Document Type: Article

References (35)

1. Wiseman LR, Faulds D. Ebastine: a review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders. Drugs 1996; 51: 260-77.
2. Rohatagi S, Gillen M, Aubeneau M, Jan C, Pandit B, Jensen BK, Rhodes G. Effect of age and gender on the pharmacokinetics of ebastine after single and repeated dosing in healthy subjects. Int J Clin Pharmacol Ther 2001; 39: 126-34.
3. Yamaguchi T, Hashizume T, Matsuda M, Sakashita M, Fujii T, Sekine Y, Nakashima M, Uematsu T. Pharmacokinetics of the H1-receptor antagonist ebastine and its active metabolite carebastine in healthy subjects. Arzneimittelforschung 1994; 44: 59-64.
4. Fujii T, Matsumoto S, Amejima H, Hatoyama T, Nakao M, Kagemoto A, Tanaka K, Miyazaki H. Absorption, distribution, metabolism and excretion of [14C]ebastine after a single administration in rats. Arzneimittelforschung 1994; 44: 527-38.
5. 1-receptor antagonist ebastine and its active metabolite carebastine in rats, guinea pigs, dogs and monkeys. Arzneimittelforschung 1994; 44: 55-9.
6. Hashizume T, Mise M, Terauchi Y, O L, Fujii T, Miyazaki H, Inaba T. N-Dealkylation and hydroxylation of ebastine by human liver cytochrome P450. Drug Metab Dispos 1998; 26: 566-71.
7. Hashizume T, Imaoka S, Mise M, Terauchi Y, Fujii T, Miyazaki H, Kamataki T, Funae Y. Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. J Pharmacol Exp Ther 2002; 300: 298-304.
8. King LM, Ma J, Srettabunjong S, Graves J, Bradbury JA, Li L, Spiecker M, Liao JK, Mohrenweiser H, Zeldin DC. Cloning of CYP2J2 gene and identification of functional polymorphisms. Mol Pharmacol 2002; 61: 840-52.
9. Imamura Y, Shimizu K, Yamashita F, Yamaoka K, Takakura Y, Hashida M. Transport characteristics of ebastine and its metabolites across human intestinal epithelial Caco-2 cell monolayers. Biol Pharm Bull 2001; 24: 930-4.
10. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473-8.
11. Siegsmund M, Brinkmann U, Schaffeler E, Weirich G, Schwab M, Eichelbaum M, Fritz P, Burk O, Decker J, Alken P, Rothenpieler U, Kerb R, Hoffmeyer S, Brauch H. Association of the P-glycoprotein transporter MDR1 (C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol 2002; 13: 1847-54.
12. Siegmund W, Ludwig K, Giessmann T, Dazert P, Schroeder E, Sperker B, Warzok R, Kroemer HK, Cascorbi I. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 2002; 72: 572-83.
13. Gerloff T, Schaefer M, Johne A, Oselin K, Meisel C, Cascorbi I, Roots I. MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br J Clin Pharmacol 2002; 54: 610-6.
14. Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, He K, Lown KS, Woster PM, Rahman A, Thummel KE, Fisher JM, Hollenberg PF, Watkins PB. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos 1997; 25: 1228-33.
15. Cavalli SA, Hirata MH, Hirata RD. Detection of MboII polymorphism at the 5' promoter region of CYP3A4. Clin Chem 2001; 47: 348-51.
16. van Schaik RH, van der Heiden IP, van den Anker JN, Lindemans J. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 2002; 48: 1668-71.
17. Agundez JA, Martinez C, Ledesma MC, Ladona MG, Ladero JM, Benitez J. Genetic basis for differences in debrisoquin polymorphism between a Spanish and other white populations. Clin Pharmacol Ther 1994; 55: 412-7.
18. Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004; 5: 243-72.
19. von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on doseadjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 2001; 47: 1048-52.
20. Matsuda M, Mizuki Y, Terauchi Y. Simultaneous determination of the histamine H1-receptor antagonist ebastine and its two metabolites, carebastine and hydroxyebastine, in human plasma using high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 2001; 757: 173-9.
21. Garcia-Martin E, Martinez C, Pizarro RM, Garcia-Gamito FJ, Gullsten H, Raunio H, Agundez JA. CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clin Pharmacol Ther 2002; 71: 196-204.
22. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genet 2001; 27: 383-91.
23. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, Brown MB, Guo W, Watkins PB. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997; 99: 2545-53.
24. Honda Y, Ushigome F, Koyabu N, Morimoto S, Shoyama Y, Uchiumi T, Kuwano M, Ohtani H, Sawada Y. Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. Br J Pharmacol 2004; 143: 856-64.
25. Lasseter KC, Dilzer SC, Vargas R, Waldman S, Noveck RJ. Pharmacokinetics and safety of ebastine in patients with impaired hepatic function compared with healthy volunteers: a phase I open-label study. Clin Pharmacokinet 2004; 43: 121-9.
26. Hashizume T, Mise M, Matsumoto S, Terauchi Y, Fujii T, Imaoka S, Funae Y, Kamataki T, Miyazaki H. A novel cytochrome P450 enzyme responsible for the metabolism of ebastine in monkey small intestine. Drug Metab Dispos 2001; 29: 798-805.
27. Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999; 39: 1-17.
28. Tamai I, Kido Y, Yamashita J, Sai Y, Tsuji A. Blood-brain barrier transport of H1-antagonist ebastine and its metabolite carebastine. J Drug Target 2000; 8: 383-93.
29. McCune JS, Lindley C, Decker JL, Williamson KM, Meadowcroft AM, Graff D, Sawyer WT, Blough DK, Pieper JA. Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan. J Clin Pharmacol 2001; 41: 723-31.
30. Inagaki K, Inagaki M, Kataoka T, Sekido I, Gill MA, Nishida M. A wide interindividual variability of urinary 6beta-hydroxycortisol to free cortisol in 487 healthy Japanese subjects in near basal condition. Ther Drug Monit 2002; 24: 722-7.
31. Zhu B, Liu ZQ, Chen GL, Chen XP, Ou-Yang DS, Wang LS, Huang SL, Tan ZR, Zhou HH. The distribution and gender difference of CYP3A activity in Chinese subjects. Br J Clin Pharmacol 2003; 55: 264-9.
32. Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet 2003; 42: 107-21.
33. Verster JC, Volkerts ER. Antihistamines and driving ability: evidence from on-the-road driving studies during normal traffic. Ann Allergy Asthma Immunol 2004; 92: 294-303; quiz 303-5, 355.
34. Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC, Malaise J, Lison D, Squifflet JP, Wallemacq P. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004; 14: 147-54.
35. Romiti N, Tramonti G, Donati A, Chieli E. Effects of grapefruit juice on the multidrug transporter P-glycoprotein in the human proximal tubular cell line HK-2. Life Sci 2004; 76: 293-302.